Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon Cancer

Xiaorong Ding, Hua Liu, Ying Yuan, Qin Zhong, Xiaomin ZhongFrontiers in Oncology 2022 · DOI

TL;DR

Researchers have identified GFPT2 as a critical driver of poor outcomes in colon cancer. The study reveals that high levels of this enzyme not only predict shorter patient survival but also actively reshape the tumor microenvironment into an immunosuppressive "shield" that helps cancer evade the immune system and resist certain drugs.

What Problem Does This Paper Address?

Colon cancer remains one of the most prevalent and lethal malignancies globally. While we have made strides in treatment, a major challenge is the Tumor Microenvironment (TME)—the complex ecosystem of stromal cells, immune cells, and signaling molecules surrounding a tumor.

The authors focused on GFPT2 (Glutamine-fructose-6-phosphate transaminase 2), the rate-limiting enzyme in the hexosamine biosynthetic pathway. While GFPT2 was known to be involved in metabolism and some other cancers, its specific role in colon cancer prognosis and its influence on the TME remained a "black box." The researchers sought to determine if GFPT2 could serve as a reliable biomarker for patient survival and a potential target for personalized therapy.

Methods

The study combined traditional "wet lab" experiments with large-scale "dry lab" bioinformatics:

  • Clinical Validation: The team examined protein levels in tissues from 83 colon cancer patients using Immunohistochemistry (IHC) and Western Blot assays to compare cancerous vs. normal (paraneoplastic) tissues.
  • Bioinformatics Pipeline: They analyzed transcriptomic and clinical data from The Cancer Gene Atlas (TCGA) for 329 colon adenocarcinoma patients.
  • Microenvironment Analysis: They used algorithms like ESTIMATE (to calculate stromal and immune scores) and CIBERSORT (to quantify specific immune cell types).
  • Single-Cell Resolution: To see exactly which cells express GFPT2, they utilized the TISCH database for single-cell RNA sequencing.
  • Drug Sensitivity: They cross-referenced GFPT2 expression with the CellMiner database to predict how tumors might respond to various FDA-approved and experimental drugs.

Datasets

  • TCGA-COAD: The primary source for patient survival and gene expression data.
  • CCLE (Cancer Cell Line Encyclopedia): Used to validate GFPT2-related pathways in intestinal cancer cell lines.
  • TISCH (Tumor Immune Single Cell Center): Provided single-cell data to pinpoint GFPT2 expression in specific cell subpopulations.
  • CellMiner: Provided drug sensitivity profiles for correlation with gene expression.
  • In-house Cohort: 83 patients from The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University.

Key Insights and Ideas

  • A Marker for Aggression: High GFPT2 expression isn't just a random metabolic byproduct; it correlates strongly with advanced TNM stages, larger tumor sizes, and increased lymph node metastasis.
  • The CAF Connection: Perhaps the most striking insight is that GFPT2 is highly expressed in Cancer-Associated Fibroblasts (CAFs). These are "helper" cells that tumors recruit to build a supportive physical and chemical structure, promoting invasion and metastasis.
  • Immunological "Cold" Zones: High GFPT2 levels were positively correlated with immunosuppressive cells (like M0 Macrophages and Neutrophils) and markers of T-cell exhaustion (such as LAG3 and PDCD1/PD-1). This suggests GFPT2 helps the tumor create an environment where the body's natural defenses are "turned off."
  • Pathway Hijacking: The study found that GFPT2 is linked to the JAK/STAT and MAPK signaling pathways, which are well-known drivers of cell proliferation and survival in cancer.

Key Results

  • Survival Impact: Patients with high GFPT2 expression had significantly lower Overall Survival (OS) compared to those with low expression ($p = 0.028$).
  • TME Correlation: GFPT2 showed a remarkably strong positive correlation with stromal scores ($R = 0.89$) and immune scores ($R = 0.64$), while being negatively correlated with tumor purity.
  • Drug Sensitivity: GFPT2 expression was a "judgment" for drug response. High levels were associated with increased sensitivity to drugs like Deforolimius and SGX-523, but increased resistance to others like CUDC-305.
  • Statistical Significance: The association between GFPT2 and advanced TNM stage was highly significant ($p = 0.005$).

Limitations and Future Work

While the study provides a comprehensive map of GFPT2’s role, the authors acknowledge several limitations:

  1. Retrospective Nature: The clinical data was collected retrospectively; prospective trials are needed to confirm these findings.
  2. Lack of Mechanism: While the correlations are strong, the paper does not perform "knockdown" or "overexpression" experiments in animal models to prove exactly how GFPT2 causes these changes.
  3. Future Directions: The authors suggest that future research should focus on cellular and animal experiments to further confirm if inhibiting GFPT2 can actually slow tumor growth or "re-heat" the immune environment to make immunotherapy more effective.

Summary updated

Abstract

Our work reveals the roles of GFPT2 in tumorigenesis, particularly in immune response, TME and drug resistance, which are crucial for the development of customized cancer therapies.
BibTeX
@inproceedings{ding2022roles,
  author = {Xiaorong Ding and Hua Liu and Ying Yuan and Qin Zhong and Xiaomin Zhong},
  title = {{Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon Cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.811559},
}
Figure